Hosted by Sarah Mitchell & James Carter
Downloads
More from: Heart Failure Deep Dive Series
How Four Drugs Beat Heart Failure
Four drug classes — ARNi, beta-blocker, MRA, SGLT2 inhibitor — have together produced a 73% reduction in cardiovascular death and hospitalisation versus placebo in HFrEF. Sarah Mitchell and James Carter unpack why each drug works, what the landmark trials showed, and why clinical inertia is still the biggest barrier to optimal care.
Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating the metabolic environment is the new paradigm for HFpEF.
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell and James Carter cover ADHF management, cardiogenic shock, and how to prevent the revolving door.
- EMPEROR-Preserved and DELIVER: both SGLT2 inhibitors significantly reduce HF hospitalisation in HFpEF - first drugs to do so after 20 years of failed trials
- FINEARTS-HF 2024: finerenone (non-steroidal MRA) also reduces worsening HF events in HFmrEF/HFpEF
- HFpEF driven by inflammation, fibrosis, metabolic comorbidities - not neurohormonal activation; explains why earlier drug classes failed
- Structured HFpEF diagnosis using HFA-PEFF or H2FPEF algorithms is now clinically important as effective treatments exist
POD-2026-014 - 06/26
Cite This Article
Team TLSFE. Diabetes drugs for stiff heart failure. The Life Science Feed. Published June 1, 2026. Updated June 1, 2026. Accessed June 3, 2026. https://thelifesciencefeed.com/cardiology/heart-failure/research/diabetes-drugs-for-stiff-heart-failure.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Podcast Disclaimer
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
[1] Anker SD et al. EMPEROR-Preserved. N Engl J Med. 2021;385:1451-1461
[2] Solomon SD et al. DELIVER. N Engl J Med. 2022;387:1089-1098
[3] Lam CSP et al. EMPEROR-DELIVER pooled. Nat Med. 2022;28:2726-2734
[4] Solomon SD et al. FINEARTS-HF. N Engl J Med. 2024
[5] McDonagh TA et al. 2023 Focused Update ESC HF Guidelines. Eur Heart J. 2023
